Literature DB >> 10785510

Arterial paclitaxel distribution and deposition.

C J Creel1, M A Lovich, E R Edelman.   

Abstract

Successful implementation of local arterial drug delivery requires transmural distribution of drug. The physicochemical properties of the applied compound, which govern its transport and tissue binding, become as important as the mode of delivery. Hydrophilic compounds distribute freely but are cleared rapidly. Hydrophobic drugs, insoluble in aqueous solutions, bind to fixed tissue elements, potentially prolonging tissue residence and biological effect. Paclitaxel is such a hydrophobic compound, with tremendous therapeutic potential against proliferative vascular disease. We hypothesized that the recent favorable preclinical data with this compound may derive in part from preferential tissue binding as a result of unique physicochemical properties. The arterial transport of paclitaxel was quantified through application ex vivo and measurement of the subsequent transmural distribution. Arterial paclitaxel deposition at equilibrium varied across the arterial wall and was everywhere greater in concentration than in the applied drug source. Permeation into the wall increased with time, from 15 minutes to 4 hours, and varied with the origin of delivery. In contrast to hydrophilic compounds, the concentration in tissue exceeds the applied concentration and the rate of transport was markedly slower. Furthermore, endovascular and perivascular paclitaxel application led to markedly differential deposition across the blood vessel wall. These data suggest that paclitaxel interacts with arterial tissue elements as it moves under the forces of diffusion and convection and can establish substantial partitioning and spatial gradients across the tissue. The complexity of paclitaxel pharmacokinetics requires in-depth investigation if this drug is to reach its full clinical potential in proliferative vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10785510     DOI: 10.1161/01.res.86.8.879

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  43 in total

1.  Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study.

Authors:  Ashok S Thakkar; Atul D Abhyankar; Sameer I Dani; Darshan N Banker; Parvinder I Singh; Sanjay A Parmar; Anita A Mehta
Journal:  Indian Heart J       Date:  2012 May-Jun

2.  Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel.

Authors:  Andrew D Levin; Neda Vukmirovic; Chao-Wei Hwang; Elazer R Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-14       Impact factor: 11.205

3.  Stent elution rate determines drug deposition and receptor-mediated effects.

Authors:  Abraham R Tzafriri; Adam Groothuis; G Sylvester Price; Elazer R Edelman
Journal:  J Control Release       Date:  2012-05-26       Impact factor: 9.776

4.  Paclitaxel induces thrombomodulin downregulation in human aortic endothelial cells.

Authors:  Huang-Joe Wang; Te-Ling Lu; Haimei Huang; Huey-Chun Huang
Journal:  Tex Heart Inst J       Date:  2011

5.  Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution.

Authors:  Brinda Balakrishnan; John F Dooley; Gregory Kopia; Elazer R Edelman
Journal:  J Control Release       Date:  2007-07-05       Impact factor: 9.776

6.  Opportunities and limitations of drug-coated balloons in interventional therapies.

Authors:  B Scheller
Journal:  Herz       Date:  2011-05       Impact factor: 1.443

7.  Calcified plaque modification alters local drug delivery in the treatment of peripheral atherosclerosis.

Authors:  Abraham R Tzafriri; Fernando Garcia-Polite; Brett Zani; James Stanley; Benny Muraj; Jennifer Knutson; Robert Kohler; Peter Markham; Alexander Nikanorov; Elazer R Edelman
Journal:  J Control Release       Date:  2017-09-01       Impact factor: 9.776

8.  Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy.

Authors:  Vijaya B Kolachalama; Stephen D Pacetti; Joseph W Franses; John J Stankus; Hugh Q Zhao; Tarek Shazly; Alexander Nikanorov; Lewis B Schwartz; Abraham R Tzafriri; Elazer R Edelman
Journal:  Circulation       Date:  2013-04-12       Impact factor: 29.690

9.  Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients.

Authors:  Abraham R Tzafriri; Benny Muraj; Fernando Garcia-Polite; Antonio G Salazar-Martín; Peter Markham; Brett Zani; Anna Spognardi; Mazen Albaghdadi; Steve Alston; Elazer R Edelman
Journal:  Biomaterials       Date:  2020-08-20       Impact factor: 12.479

10.  Location-dependent coronary artery diffusive and convective mass transport properties of a lipophilic drug surrogate measured using nonlinear microscopy.

Authors:  Joseph T Keyes; Bruce R Simon; Jonathan P Vande Geest
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.